Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 1063

1.

Patient-derived tumor immune microenvironments in patient-derived xenografts of lung cancer.

Pu X, Zhang R, Wang L, Chen Y, Xu Y, Pataer A, Meraz IM, Zhang X, Wu S, Wu L, Su D, Mao W, Heymach JV, Roth JA, Swisher SG, Fang B.

J Transl Med. 2018 Nov 26;16(1):328. doi: 10.1186/s12967-018-1704-3.

2.

A 5-MicroRNA Signature Identified from Serum MicroRNA Profiling Predicts Survival in Patients with Advanced Stage Non-Small Cell Lung Cancer.

Zhang Y, Roth JA, Yu H, Ye Y, Xie K, Zhao H, Chang DW, Huang M, Li H, Qu J, Wu X.

Carcinogenesis. 2018 Nov 14. doi: 10.1093/carcin/bgy132. [Epub ahead of print]

PMID:
30428030
3.

Inhibition of thioredoxin/thioredoxin reductase induces synthetic lethality in lung cancers with compromised glutathione homeostasis.

Yan X, Zhang X, Wang L, Zhang R, Pu X, Wu S, Li L, Tong P, Wang J, Meng Q, Jensen VB, Girard L, Minna JD, Roth JA, Swisher SG, Heymach JV, Fang B.

Cancer Res. 2018 Nov 6. pii: canres.1938.2018. doi: 10.1158/0008-5472.CAN-18-1938. [Epub ahead of print]

PMID:
30401714
4.

Introduction to Machine Learning in Digital Healthcare Epidemiology.

Roth JA, Battegay M, Juchler F, Vogt JE, Widmer AF.

Infect Control Hosp Epidemiol. 2018 Dec;39(12):1457-1462. doi: 10.1017/ice.2018.265. Epub 2018 Nov 5.

PMID:
30394238
5.

Local Consolidation Therapy (LCT) After First Line Tyrosine Kinase Inhibitor (TKI) for Patients With EGFR Mutant Metastatic Non-small-cell Lung Cancer (NSCLC).

Elamin YY, Gomez DR, Antonoff MB, Robichaux JP, Tran H, Shorter MK, Bohac JM, Negrao MV, Le X, Rinsurogkawong W, Lewis J, Lacerda L, Roarty EB, Swisher SG, Roth JA, Zhang J, Papadimitrakopoulou V, Heymach JV.

Clin Lung Cancer. 2018 Sep 24. pii: S1525-7304(18)30260-2. doi: 10.1016/j.cllc.2018.09.015. [Epub ahead of print]

PMID:
30343004
6.

Frequent Door Openings During Cardiac Surgery are Associated with Increased Risk for Surgical Site Infection: A Prospective Observational Study.

Roth JA, Juchler F, Dangel M, Eckstein FS, Battegay M, Widmer AF.

Clin Infect Dis. 2018 Oct 13. doi: 10.1093/cid/ciy879. [Epub ahead of print]

PMID:
30321301
7.

Validation of the 12-gene Predictive Signature for Adjuvant Chemotherapy Response in Lung Cancer.

Xie Y, Lu W, Wang S, Tang X, Tang H, Zhou Y, Moran C, Behrens C, Roth JA, Zhou Q, Johnson DH, Swisher SG, Heymach JV, Papadimitrakopoulou VA, Xiao G, Minna JD, Wistuba II.

Clin Cancer Res. 2018 Oct 4. doi: 10.1158/1078-0432.CCR-17-2543. [Epub ahead of print]

PMID:
30287547
8.

Cost-effectiveness of axicabtagene ciloleucel for adult patients with relapsed or refractory large B-cell lymphoma in the United States.

Roth JA, Sullivan SD, Lin VW, Bansal A, Purdum AG, Navale L, Cheng P, Ramsey SD.

J Med Econ. 2018 Dec;21(12):1238-1245. doi: 10.1080/13696998.2018.1529674. Epub 2018 Oct 16. Erratum in: J Med Econ. 2018 Dec;21(12):1255.

PMID:
30260711
9.

Comment on "The domestic cat antibody responseto FHV-1 increases with age".

Roth JA.

Vet Immunol Immunopathol. 2018 Sep;203:65. doi: 10.1016/j.vetimm.2018.08.007. Epub 2018 Aug 20. No abstract available.

PMID:
30243376
10.

Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC.

Le X, Puri S, Negrao MV, Nilsson MB, Robichaux J, Boyle T, Hicks JK, Lovinger KL, Roarty E, Rinsurongkawong W, Tang M, Sun H, Elamin Y, Lacerda LC, Lewis J, Roth JA, Swisher SG, Lee JJ, William WN Jr, Glisson BS, Zhang J, Papadimitrakopoulou VA, Gray JE, Heymach JV.

Clin Cancer Res. 2018 Dec 15;24(24):6195-6203. doi: 10.1158/1078-0432.CCR-18-1542. Epub 2018 Sep 18.

PMID:
30228210
11.

Plea for Standardized Reporting and Justification of Propensity Score Methods.

Roth JA, Juchler F, Widmer AF, Battegay M.

Clin Infect Dis. 2018 Aug 22. doi: 10.1093/cid/ciy700. [Epub ahead of print] No abstract available.

PMID:
30137235
12.

Costs versus earnings in colon surgery and coronary artery bypass grafting under a prospective payment system: Sufficient financial incentives to reduce surgical site infections?

Juchler F, Roth JA, Schweiger A, Dangel M, Gugliotta M, Battegay M, Eckstein FS, Kettelhack C, Abshagen C, Hug BL, Boyce JM, Widmer AF.

Infect Control Hosp Epidemiol. 2018 Oct;39(10):1246-1249. doi: 10.1017/ice.2018.179. Epub 2018 Aug 22.

PMID:
30131085
13.

Perioperative Outcomes for Stage I Non-Small Cell Lung Cancer: Differences Between Men and Women.

Nelson DB, Lapid DJ, Mitchell KG, Correa AM, Hofstetter WL, Mehran RJ, Rice DC, Sepesi B, Walsh GL, Vaporciyan AA, Swisher SG, Roth JA, Antonoff MB.

Ann Thorac Surg. 2018 Nov;106(5):1499-1503. doi: 10.1016/j.athoracsur.2018.06.070. Epub 2018 Aug 15.

PMID:
30118712
14.

Predictors of survival after resection of primary sarcomas of the chest wall-A large, single-institution series.

Shewale JB, Mitchell KG, Nelson DB, Conley AP, Rice DC, Antonoff MB, Hofstetter WL, Walsh GL, Swisher SG, Roth JA, Mehran RJ, Vaporciyan AA, Weissferdt A, Sepesi B.

J Surg Oncol. 2018 Sep;118(3):518-524. doi: 10.1002/jso.25162. Epub 2018 Aug 15.

PMID:
30109699
15.

A qualitative study exploring patient motivations for screening for lung cancer.

Roth JA, Carter-Harris L, Brandzel S, Buist DSM, Wernli KJ.

PLoS One. 2018 Jul 5;13(7):e0196758. doi: 10.1371/journal.pone.0196758. eCollection 2018.

16.

The Cumulative Impact of Harm Reduction on the Swiss HIV Epidemic: Cohort Study, Mathematical Model, and Phylogenetic Analysis.

Marzel A, Kusejko K, Weber R, Bruggmann P, Rauch A, Roth JA, Bernasconi E, Calmy A, Cavassini M, Hoffmann M, Böni J, Yerly S, Klimkait T, Perreau M, Günthard HF, Kouyos RD; Swiss HIV Cohort Study .

Open Forum Infect Dis. 2018 May 19;5(5):ofy078. doi: 10.1093/ofid/ofy078. eCollection 2018 May.

17.

Major pathologic response and RAD51 predict survival in lung cancer patients receiving neoadjuvant chemotherapy.

Pataer A, Shao R, Correa AM, Behrens C, Roth JA, Vaporciyan AA, Wistuba II, Swisher SG.

Cancer Med. 2018 Jun;7(6):2405-2414. doi: 10.1002/cam4.1505. Epub 2018 Apr 19.

18.

Genetic variants in cytokine signaling pathways and clinical outcomes in early-stage lung cancer patients.

Sepesi B, Ye Y, Mitchell KG, Zhang L, Gu J, Ji L, Antonoff MB, Hofstetter WL, Rice DC, Mehran RJ, Walsh GL, Vaporciyan AA, Swisher SG, Roth JA, Wu X.

J Thorac Cardiovasc Surg. 2018 Jun;155(6):2635-2645.e15. doi: 10.1016/j.jtcvs.2018.02.015. Epub 2018 Feb 15.

PMID:
29548588
19.

Clinicoradiographic Predictors of Aggressive Biology in Lung Cancer With Ground Glass Components.

Nelson DB, Godoy MCB, Benveniste MF, Shewale JB, Spicer JD, Mitchell KG, Hofstetter WL, Mehran RJ, Rice DC, Sepesi B, Walsh GL, Vaporciyan AA, Swisher SG, Roth JA, Antonoff MB.

Ann Thorac Surg. 2018 Jul;106(1):235-241. doi: 10.1016/j.athoracsur.2018.02.020. Epub 2018 Mar 11.

PMID:
29534957
20.

Enhanced Recovery Decreases Pulmonary and Cardiac Complications After Thoracotomy for Lung Cancer.

Van Haren RM, Mehran RJ, Mena GE, Correa AM, Antonoff MB, Baker CM, Woodard TC, Hofstetter WL, Roth JA, Sepesi B, Swisher SG, Vaporciyan AA, Walsh GL, Rice DC.

Ann Thorac Surg. 2018 Jul;106(1):272-279. doi: 10.1016/j.athoracsur.2018.01.088. Epub 2018 Mar 9.

PMID:
29530770
21.

Overuse of antimicrobial prophylaxis in low-risk patients undergoing transurethral resection of the prostate.

Bausch K, Roth JA, Seifert HH, Widmer AF.

Swiss Med Wkly. 2018 Feb 23;148:w14594. doi: 10.4414/smw.2018.14594. eCollection 2018.

22.

Comparison of outcomes between muscle-sparing thoracotomy and video-assisted thoracic surgery in patients with cT1 N0 M0 lung cancer.

Mehran RJ, Martin LW, Roth JA.

J Thorac Cardiovasc Surg. 2018 Mar;155(3):1307. doi: 10.1016/j.jtcvs.2017.10.039. No abstract available.

PMID:
29452469
23.

Natural History of Ground-Glass Lesions Among Patients With Previous Lung Cancer.

Shewale JB, Nelson DB, Rice DC, Sepesi B, Hofstetter WL, Mehran RJ, Vaporciyan AA, Walsh GL, Swisher SG, Roth JA, Antonoff MB.

Ann Thorac Surg. 2018 Jun;105(6):1671-1677. doi: 10.1016/j.athoracsur.2018.01.031. Epub 2018 Feb 9.

PMID:
29432718
24.

Defect Rates in Touchless Versus Mechanical Hand Hygiene Dispensers.

Roth JA, Batzer B, Hug BL, Widmer AF.

Infect Control Hosp Epidemiol. 2018 Mar;39(3):359-360. doi: 10.1017/ice.2017.306. Epub 2018 Jan 24. No abstract available.

PMID:
29363435
25.

TUSC2 Immunogene Therapy Synergizes with Anti-PD-1 through Enhanced Proliferation and Infiltration of Natural Killer Cells in Syngeneic Kras-Mutant Mouse Lung Cancer Models.

Meraz IM, Majidi M, Cao X, Lin H, Li L, Wang J, Baladandayuthapani V, Rice D, Sepesi B, Ji L, Roth JA.

Cancer Immunol Res. 2018 Feb;6(2):163-177. doi: 10.1158/2326-6066.CIR-17-0273. Epub 2018 Jan 16.

26.

Overcoming resistance to anti-PD immunotherapy in a syngeneic mouse lung cancer model using locoregional virotherapy.

Yan X, Wang L, Zhang R, Pu X, Wu S, Yu L, Meraz IM, Zhang X, Wang JF, Gibbons DL, Mehran RJ, Swisher SG, Roth JA, Fang B.

Oncoimmunology. 2017 Oct 31;7(1):e1376156. doi: 10.1080/2162402X.2017.1376156. eCollection 2017.

27.

TUSC2 downregulates PD-L1 expression in non-small cell lung cancer (NSCLC).

Cao X, Zhao Y, Wang J, Dai B, Gentile E, Lin J, Pu X, Ji L, Wu S, Meraz I, Majidi M, Roth JA.

Oncotarget. 2017 Nov 21;8(64):107621-107629. doi: 10.18632/oncotarget.22581. eCollection 2017 Dec 8.

28.

Anti-leukemia activity of NSC-743380 in SULT1A1-expressing acute myeloid leukemia cells is associated with inhibitions of cFLIP expression and PI3K/AKT/mTOR activities.

Huang X, Cao M, Wu S, Wang L, Hu J, Mehran RJ, Roth JA, Swisher SG, Wang RY, Kantarjian HM, Andreeff M, Sun X, Fang B.

Oncotarget. 2017 Nov 1;8(60):102150-102160. doi: 10.18632/oncotarget.22235. eCollection 2017 Nov 24.

29.

Direct Costs of a Contact Isolation Day: A Prospective Cost Analysis at a Swiss University Hospital.

Roth JA, Hornung-Winter C, Radicke I, Hug BL, Biedert M, Abshagen C, Battegay M, Widmer AF.

Infect Control Hosp Epidemiol. 2018 Jan;39(1):101-103. doi: 10.1017/ice.2017.258. Epub 2017 Dec 18.

PMID:
29249218
30.

Influence of induction chemotherapy in trimodality therapy-eligible oesophageal cancer patients: secondary analysis of a randomised trial.

Shimodaira Y, Slack RS, Harada K, Chen HC, Sagebiel T, Bhutani MS, Lee JH, Weston B, Elimova E, Lin Q, Amlashi FG, Mizrak Kaya D, Blum MA, Roth JA, Swisher SG, Skinner HD, Hofstetter WL, Rogers JE, Mares J, Thomas I, Maru DM, Komaki R, Walsh G, Ajani JA.

Br J Cancer. 2018 Feb 6;118(3):331-337. doi: 10.1038/bjc.2017.423. Epub 2017 Dec 12.

PMID:
29235564
31.

Early Metabolic Change after Induction Chemotherapy Predicts Histologic Response and Prognosis in Patients with Esophageal Cancer: Secondary Analysis of a Randomized Trial.

Harada K, Wang X, Shimodaira Y, Sagebiel T, Bhutani MS, Lee JH, Weston B, Elimova E, Lin Q, Amlashi FG, Mizrak Kaya D, Lopez A, Blum Murphy MA, Roth JA, Swisher SG, Skinner HD, Hofstetter WL, Rogers JE, Thomas I, Maru DM, Komaki R, Walsh G, Ajani JA.

Target Oncol. 2018 Feb;13(1):99-106. doi: 10.1007/s11523-017-0540-3.

PMID:
29218623
32.

Predictors of trimodality therapy and trends in therapy for malignant pleural mesothelioma.

Nelson DB, Rice DC, Niu J, Atay SM, Vaporciyan AA, Antonoff MB, Hofstetter WL, Walsh GL, Swisher SG, Roth JA, Tsao AS, Gomez DR, Giordano SH, Mehran RJ, Sepesi B.

Eur J Cardiothorac Surg. 2018 May 1;53(5):960-966. doi: 10.1093/ejcts/ezx427.

PMID:
29211849
33.

Variants with a low allele frequency detected in genomic DNA affect the accuracy of mutation detection in cell-free DNA by next-generation sequencing.

Wang JF, Pu X, Zhang X, Chen K, Xi Y, Wang J, Mao X, Zhang J, Heymach JV, Antonoff MB, Hofstetter WL, Mehran RJ, Rice DC, Roth JA, Sepesi B, Swisher SG, Vaporciyan AA, Walsh GL, Meng QH, Shaw KR, Eterovic AK, Fang B.

Cancer. 2018 Mar 1;124(5):1061-1069. doi: 10.1002/cncr.31152. Epub 2017 Nov 27.

PMID:
29178133
34.

Circulating metabolite profiles to predict overall survival in advanced non-small cell lung cancer patients receiving first-line chemotherapy.

Shen J, Ye Y, Chang DW, Huang M, Heymach JV, Roth JA, Wu X, Zhao H.

Lung Cancer. 2017 Dec;114:70-78. doi: 10.1016/j.lungcan.2017.10.018. Epub 2017 Nov 2.

35.

Perioperative Outcomes of Patients Undergoing Lobectomy on Clopidogrel.

Atay SM, Correa AM, Hofstetter WL, Mehran RJ, Rice DC, Roth JA, Sepesi B, Swisher SG, Vaporciyan AA, Walsh G, Antonoff MB.

Ann Thorac Surg. 2017 Dec;104(6):1821-1828. doi: 10.1016/j.athoracsur.2017.05.021. Epub 2017 Oct 5.

PMID:
28987393
36.

Serum MicroRNA-150 Predicts Prognosis for Early-Stage Non-Small Cell Lung Cancer and Promotes Tumor Cell Proliferation by Targeting Tumor Suppressor Gene SRCIN1.

Zhang L, Lin J, Ye Y, Oba T, Gentile E, Lian J, Wang J, Zhao Y, Gu J, Wistuba II, Roth JA, Ji L, Wu X.

Clin Pharmacol Ther. 2018 Jun;103(6):1061-1073. doi: 10.1002/cpt.870. Epub 2017 Oct 16.

PMID:
28891208
37.

A miR-SNP biomarker linked to an increased lung cancer survival by miRNA-mediated down-regulation of FZD4 expression and Wnt signaling.

Lin J, Zandi R, Shao R, Gu J, Ye Y, Wang J, Zhao Y, Pertsemlidis A, Wistuba II, Wu X, Roth JA, Ji L.

Sci Rep. 2017 Aug 22;7(1):9029. doi: 10.1038/s41598-017-09604-4.

38.

Long-Term Survival Outcomes of Cancer-Directed Surgery for Malignant Pleural Mesothelioma: Propensity Score Matching Analysis.

Nelson DB, Rice DC, Niu J, Atay S, Vaporciyan AA, Antonoff M, Hofstetter WL, Walsh GL, Swisher SG, Roth JA, Tsao A, Gomez D, Giordano SH, Mehran R, Sepesi B.

J Clin Oncol. 2017 Oct 10;35(29):3354-3362. doi: 10.1200/JCO.2017.73.8401. Epub 2017 Aug 17.

PMID:
28817374
39.

Value of the Pitt Bacteraemia Score to predict short-term mortality in Staphylococcus aureus bloodstream infection: a validation study.

Roth JA, Tschudin-Sutter S, Dangel M, Frei R, Battegay M, Widmer AF.

Swiss Med Wkly. 2017 Aug 10;147:w14482. doi: 10.4414/smw.2017.14482. eCollection 2017.

40.

Cationic liquid crystalline nanoparticles for the delivery of synthetic RNAi-based therapeutics.

Gentile E, Oba T, Lin J, Shao R, Meng F, Cao X, Lin HY, Mourad M, Pataer A, Baladandayuthapani V, Cai D, Roth JA, Ji L.

Oncotarget. 2017 Jul 18;8(29):48222-48239. doi: 10.18632/oncotarget.18421.

41.

MELD score as a predictor of mortality, length of hospital stay, and disease burden: A single-center retrospective study in 39,323 inpatients.

Roth JA, Chrobak C, Schädelin S, Hug BL.

Medicine (Baltimore). 2017 Jun;96(24):e7155. doi: 10.1097/MD.0000000000007155.

42.

The effect of manganese exposure in Atp13a2-deficient mice.

Fleming SM, Santiago NA, Mullin EJ, Pamphile S, Karkare S, Lemkuhl A, Ekhator OR, Linn SC, Holden JG, Aga DS, Roth JA, Liou B, Sun Y, Shull GE, Schultheis PJ.

Neurotoxicology. 2018 Jan;64:256-266. doi: 10.1016/j.neuro.2017.06.005. Epub 2017 Jun 6.

PMID:
28595912
43.

Comparison of humoral and T-cell-mediated immune responses to a single dose of Bovela® live double deleted BVDV vaccine or to a field BVDV strain.

Platt R, Kesl L, Guidarini C, Wang C, Roth JA.

Vet Immunol Immunopathol. 2017 May;187:20-27. doi: 10.1016/j.vetimm.2017.03.003. Epub 2017 Mar 19.

44.

MicroRNA-related genetic variants in iron regulatory genes, dietary iron intake, microRNAs and lung cancer risk.

Zhang L, Ye Y, Tu H, Hildebrandt MA, Zhao L, Heymach JV, Roth JA, Wu X.

Ann Oncol. 2017 May 1;28(5):1124-1129. doi: 10.1093/annonc/mdx046.

45.

The Model for End-stage Liver Disease (MELD) as a predictor of short-term mortality in Staphylococcus aureus bloodstream infection: A single-centre observational study.

Roth JA, Widmer AF, Tschudin-Sutter S, Dangel M, Frei R, Battegay M, Hug BL.

PLoS One. 2017 Apr 17;12(4):e0175669. doi: 10.1371/journal.pone.0175669. eCollection 2017.

46.

Genetic variations in cancer-related significantly mutated genes and lung cancer susceptibility.

Zhang Y, Zhang L, Li R, Chang DW, Ye Y, Minna JD, Roth JA, Han B, Wu X.

Ann Oncol. 2017 Jul 1;28(7):1625-1630. doi: 10.1093/annonc/mdx161.

47.

Polytetrafluoroethylene or Acellular Dermal Matrix for Diaphragmatic Reconstruction?

Bassuner JK, Rice DC, Antonoff MB, Correa AM, Walsh GL, Vaporciyan AA, Garg N, Sepesi B, Swisher SG, Hofstetter WL, Roth JA, Mehran RJ.

Ann Thorac Surg. 2017 Jun;103(6):1710-1714. doi: 10.1016/j.athoracsur.2017.01.006. Epub 2017 Mar 31.

PMID:
28366460
48.

7-year follow-up after stereotactic ablative radiotherapy for patients with stage I non-small cell lung cancer: Results of a phase 2 clinical trial.

Sun B, Brooks ED, Komaki RU, Liao Z, Jeter MD, McAleer MF, Allen PK, Balter PA, Welsh JD, O'Reilly MS, Gomez D, Hahn SM, Roth JA, Mehran RJ, Heymach JV, Chang JY.

Cancer. 2017 Aug 15;123(16):3031-3039. doi: 10.1002/cncr.30693. Epub 2017 Mar 27.

49.

Serine Proteases Enhance Immunogenic Antigen Presentation on Lung Cancer Cells.

Peters HL, Tripathi SC, Kerros C, Katayama H, Garber HR, St John LS, Federico L, Meraz IM, Roth JA, Sepesi B, Majidi M, Ruisaard K, Clise-Dwyer K, Roszik J, Gibbons DL, Heymach JV, Swisher SG, Bernatchez C, Alatrash G, Hanash S, Molldrem JJ.

Cancer Immunol Res. 2017 Apr;5(4):319-329. doi: 10.1158/2326-6066.CIR-16-0141. Epub 2017 Mar 2.

50.

Survival Gains from First-Line Systemic Therapy in Metastatic Non-Small Cell Lung Cancer in the U.S., 1990-2015: Progress and Opportunities.

Roth JA, Goulart BH, Ravelo A, Kolkey H, Ramsey SD.

Oncologist. 2017 Mar;22(3):304-310. doi: 10.1634/theoncologist.2016-0253. Epub 2017 Feb 27.

Supplemental Content

Support Center